- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02186678
Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation (DOTATATE)
Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation: Monocentric Prospective Study
18F-FDOPA PET-CT is currently the gold standard in the evaluation of Pheochromocytomas and Paragangliomas (PHEO - PGL) since these tumors can also decarboxylate amino acids such as dihydroxyphenylalanine (DOPA). This property is common to tumors of the APUD system (Amine Precursor Uptake and Decarboxylation). In recent years, PET (Positron Emission Tomography) imaging using peptide receptors has gained an increasing role in the management of NETs. The use of somatostatin agonists, radiolabeled with gallium-68 (68Ga) enables targeting of Somatostatin receptors (SSTRs) with a PET resolution. This has improved diagnosis of SSTRs-expressing tumors, including PGLs.
In the present study, the investigators have chosen DOTATATE (Nal3-octreotate) rather than other agonists (DOTATOC and DOTANOC), because of its higher affinity for SST2 which is the most overexpressed subtype in PHEO/PGL. However, performances of 18F-FDOPA PET-CT and 68Ga-DOTATATE PET-CT have never been compared in this clinical setting.
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Marseille, France, 13005
- Assistance Publique Hopitaux de Marseille
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Age ≥ 18
- PHEO or PGL: initial staging or restaging
- Reference imaging within the last 2 months: multiphasic cervico-thoracoabdominal CT scan, 18F-FDOPA PET-CT and head and neck MRI (if head and neck localization
Exclusion Criteria:
Pregnant or breast-feeding woman
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: assesment by 68Ga-DOTATATE PET-CT
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
interest of the the contribution of 68Ga-DOTATATE PET-CT in the staging of PHEO/PGL
Time Frame: 7 months
|
The primary outcome measure is to determine the contribution of 68Ga-DOTATATE PET-CT in the staging of PHEO/PGL.
We will document the number of additional foci detected by 68Ga-DOTATATE PET-CT compared to 18F-FDOPA PET-CT.
|
7 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
assesment of 68Ga-DOTATATE PET-CT to anatomical imaging
Time Frame: 7 months
|
The secondary objective is to compare , to assess the factors influencing its sensitivity concerning the tumor location
|
7 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
assesment of 68Ga-DOTATATE PET-CT to anatomical imaging
Time Frame: 7 months
|
The third objective is to compare 68Ga-DOTATATE PET-CT to anatomical imaging, to assess the factors influencing its sensitivity concerning the genetic status,
|
7 months
|
assesment of 68Ga-DOTATATE PET-CT to anatomical imaging
Time Frame: 7 months
|
The fourth objective is to compare 68Ga-DOTATATE PET-CT to anatomical imaging, to assess the factors influencing its sensitivity concerning Somatostatin receptor expression
|
7 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: David TAIEB, MD, Assistance Publique Hopitaux de Marseille
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013-26
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Paragangliomas
-
Mercy ResearchCompletedArteriovenous Malformations | Neurofibroma | Chordoma | Meningioma | Schwannoma | Spinal Metastases | Paragangliomas | Vertebral Metastases | Benign Spinal TumorsUnited States
Clinical Trials on PET-CT
-
Peter MacCallum Cancer Centre, AustraliaMelbourne Health; Westmead Hospital; Victorian Infectious Diseases Reference...CompletedAcute Myeloid Leukemia | Febrile Neutropenia | Acute Lymphoblastic Leukemia | Haematopoietic Stem Cell Transplant, Autologous | Haematopoietic Stem Cell Transplant, AllogeneicAustralia
-
Sun Yat-sen UniversityUnknownNasopharyngeal CarcinomaChina
-
Washington University School of MedicineTerminatedCervical Cancer | Uterine Cervical Neoplasms | Uterine Cervical CancerUnited States
-
HALO DiagnosticsCompletedProstate CancerUnited States
-
Massachusetts General HospitalNational Cancer Institute (NCI)Completed
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedMalignant Neoplasm of Breast TNM Staging Distant Metastasis (M) | Untreated Bone MetastasesUnited States
-
University of UtahNational Cancer Institute (NCI)CompletedFluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) in Cancer Associated VenothromboembolismVenothromboembolismUnited States
-
The Catholic University of KoreaUnknownNon-small Cell Lung CancerKorea, Republic of
-
Peking Union Medical College HospitalRecruiting
-
Peking Union Medical College HospitalRecruitingClear Cell Renal Cell CarcinomaChina